PLIANT THERAPEUTICS, INC.
Qualité des données : 100%
PLRX
Nasdaq
Manufacturing
Chemicals
1,28 €
▼
0,07 €
(-5,19%)
Cap. Boursière: 83,89 M
Prix
1,36 €
Cap. Boursière
83,89 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—
Quick Summary
Points Clés
Debt/Equity of 0,15 — conservative balance sheet
Negative free cash flow of -128,71 M
Croissance
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Qualité
Return on Equity
-71,05%
En dessous de la moyenne du secteur (-53,53%)
ROIC-45,91%
Net MarginN/A
Op. MarginN/A
Sécurité
Debt / Equity
0,15
En dessous de la moyenne du secteur (0,31)
Current Ratio13,93
Interest Coverage-61,11
Valorisation
PE (TTM)
-0,56
Au-dessus de la moyenne du secteur (-1,48)
P/B Ratio0,42
EV/EBITDAN/A
Dividend YieldN/A
Historique des Prix
Tendances Financières
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)
Comparaison Sectorielle
vs médiane du secteur Manufacturing (1366 pairs)| Métrique | Action | Médiane du Secteur |
|---|---|---|
| P/E | -0,6 | -1,5 |
| P/B | 0,4 | 1,6 |
| ROE % | -71,1 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | 0,2 | 0,3 |
Objectif de Cours des Analystes
3 analystes
Hold
Actuel
1,28 €
Objectif
2,67 €
2,00 €
3,00 €
3,00 €
Prévisions
P/E Prévisionnel
-1,05
BPA Prévisionnel
-1,22 €
CA Est.
2,50 M
Estimations de Bénéfices
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| FY2027 |
-1,22 €
-2,17 € – 0,29 €
|
2,50 M | 6 |
| FY2026 |
-1,53 €
-1,78 € – -1,39 €
|
0,0 | 4 |
| Période | BPA Est. | CA Est. | Analystes |
|---|---|---|---|
| 2026 Q2 |
-0,37 €
-0,42 € – -0,34 €
|
0,0 | 5 |
| 2026 Q1 |
-0,36 €
-0,38 € – -0,33 €
|
0,0 | 5 |
Surprises de Résultats
Derniers 4 trimestres
| Trimestre | BPA Est. | BPA Réel | Surprise |
|---|---|---|---|
| Q42025 | -0,38 € | -0,35 € | +6,5% |
| Q32025 | -0,52 € | -0,43 € | +18,0% |
| Q22025 | -0,68 € | -0,71 € | -4,9% |
| Q12025 | -0,75 € | -0,92 € | -23,2% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0,0 | Net Income (TTM) | -149,34 M |
| ROE | -71,05% | ROA | -51,82% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -128,71 M |
| ROIC | -45,91% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,15 | Current Ratio | 13,93 |
| Interest Coverage | -61,11 | Asset Turnover | 0,00 |
| Working Capital | 227,96 M | Tangible Book Value | 200,31 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,56 | Forward P/E | N/A |
| P/B Ratio | 0,42 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -153,42% | ||
| Market Cap | 83,89 M | Enterprise Value | 20,60 M |
| Per Share | |||
| EPS (Diluted TTM) | -2,43 | Revenue / Share | 0,00 |
| FCF / Share | -2,08 | OCF / Share | -2,07 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 86,18% |
| SBC-Adj. FCF | -159,32 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0,0 | 0,0 | 1,58 M | 9,69 M | 7,57 M |
| Net Income | -149,34 M | -210,30 M | -161,34 M | -123,32 M | -97,26 M |
| EPS (Diluted) | -2,43 | -3,47 | -2,75 | -2,94 | -2,71 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -156,37 M | -228,37 M | -184,15 M | -127,20 M | -97,54 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 109,16 M | 169,31 M | 127,80 M | 96,94 M | 77,55 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 2,56 M | 3,02 M | 1,27 M | 0,0 | — |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 225,23 M | 396,95 M | 512,15 M | 350,61 M | 221,22 M |
| Total Liabilities | 44,02 M | 92,87 M | 38,58 M | 37,27 M | 22,16 M |
| Shareholders' Equity | 181,21 M | 304,08 M | 473,58 M | 313,34 M | 199,06 M |
| Total Debt | 0,0 | 30,21 M | 10,05 M | 9,93 M | — |
| Cash & Equivalents | 45,45 M | 71,19 M | 63,23 M | 33,69 M | 51,67 M |
| Current Assets | 196,45 M | 362,26 M | 505,50 M | 340,31 M | 209,44 M |
| Current Liabilities | 16,37 M | 33,22 M | 28,52 M | 23,91 M | 16,83 M |
{"event":"ticker_viewed","properties":{"ticker":"PLRX","listing_kind":"stock","pathname":"/stocks/plrx","exchange":"Nasdaq","country":"US"}}